NGNE
NeurogeneDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Primary company disclosures show meaningful execution: Breakthrough Therapy designation, full enrollment in Embolden, more than half of participants dosed, and a planned mid-2026 data update keep NGN-401 on a credible late-stage path [#IR-2026-02-26][#IR-2026-03-24].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +4.0.
What can break
Cash burn or manufacturing delays could pull financing needs forward despite runway guidance into Q1 2028
Momentum
92
Value
41
Sentiment
10
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $42.00 · Bear $9.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $80.25
Why
Momentum92 · Δ7d +4.0
Value41 · Δ7d +0.0
Sentiment10 · Δ7d +2.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
92
26% active weight
Current posture
7d trendFlat
Δ7d
+4.0
Δ21d
+9.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
10
34% active weight
Current posture
7d trendImproving
Δ7d
+2.2
Δ21d
-11.8
Why this grade
Composite grade D. Momentum 91.8 / Value 41.1 / Sentiment 10.4
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$744.07M
Beta
1.61
Shares Out
19.93M
P/E (TTM) · Derived
-8.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-8.95
Rev YoY
-100.0%
EPS YoY
+28.6%
Gross Margin
-244.8%
Op Margin
-9702.2%
Net Debt
-$259.12M
Current Ratio
13.07
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology